UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Canadian boreal forests and climate change mitigation

Environmental reviews, 2013-12, Vol.21 (4), p.293-321

2013

Volltextzugriff (PDF)

Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic

The international journal of tuberculosis and lung disease, 2009-06, Vol.13 (6), p.726

2009

Volltextzugriff (PDF)

A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation

Journal of the American College of Cardiology, 2011-01, Vol.57 (3), p.313-321

2011

Volltextzugriff (PDF)

Spontaneous and TMS-related EEG changes as new biomarkers to measure anti-epileptic drug effects

Scientific reports, 2022-02, Vol.12 (1), p.1919-1919, Article 1919

2022

Volltextzugriff (PDF)

The Mechanism of Atrial Antiarrhythmic Action of RSD1235

Journal of cardiovascular electrophysiology, 2005-11, Vol.16 (11), p.1227-1238

2005

Volltextzugriff (PDF)

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation

Journal of the American College of Cardiology, 2004-12, Vol.44 (12), p.2355-2361

2004

Volltextzugriff (PDF)

Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial

BMC cardiovascular disorders, 2016-05, Vol.16 (113), p.113-113, Article 113

2016

Volltextzugriff (PDF)

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the Asia–Pacific region: a phase 3 randomized controlled trial

Journal of cardiovascular pharmacology, 2017-02, Vol.69 (2), p.86-92

2017

Volltextzugriff (PDF)

Stabilizing Dog Populations and Improving Animal and Public Health Through a Participatory Approach in Indigenous Communities

Zoonoses and public health, 2015-09, Vol.62 (6), p.445-455

2015

Volltextzugriff (PDF)

Assessment of Potential Pharmacokinetic and Pharmacodynamic Interactions between XEN901 (a Novel NaV1.6 Selective Sodium Channel Blocker) and Phenytoin (a non-selective NaV Blocker) in Adult Healthy Subjects (4682)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Relative bioavailability, pharmacokinetic and food effect assessment of two immediate-release formulations of the NaV1.6-selective sodium channel blocker XEN901: Pediatric Granules and Adult Tablets (4840)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Pharmacokinetic and Food Effect Assessment of XEN496 (Pediatric Formulation of Ezogabine) in Healthy Adults and Relative Bioavailability Assessment with Potiga® (Adult Formulation of Ezogabine) (4918)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Two Formulations of a Novel Nav1.6 Sodium Channnel Blocker (XEN901) in Healthy Adult Subjects. (4757)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults with Focal Epilepsy (X-TOLE) (S19.004)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Children’s understanding of additive concepts

Journal of experimental child psychology, 2017-04, Vol.156, p.16-28

2017

Volltextzugriff (PDF)

TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101

Annals of clinical and translational neurology, 2019-11, Vol.6 (11), p.2164-2174

2019

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial

JAMA neurology, 2023-11, Vol.80 (11), p.1145

2023

Volltextzugriff (PDF)

Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy (S19.005)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial

Neurology and therapy, 2022-06, Vol.11 (2), p.781-796

2022

Volltextzugriff (PDF)

RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents

Cardiovascular research, 2006-06, Vol.70 (3), p.486-496

2006

Volltextzugriff (PDF)

Conceptual Knowledge of Arithmetic for Chinese- and Canadian-Educated Adults

Canadian journal of experimental psychology, 2016-12, Vol.70 (4), p.335-342

2016

Volltextzugriff (PDF)

Children's multiplication and division shortcuts: Increasing shortcut use depends on how the shortcuts are evaluated

Learning and individual differences, 2016-07, Vol.49, p.297-304

2016

Volltextzugriff (PDF)

XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker

Biomedicine & pharmacotherapy, 2018-10, Vol.106, p.510-522

2018

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(100)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Life Sciences & Biomedicine
(42)
Animals
(36)
Male
(33)
Biological And Medical Sciences
(28)
Humans
(26)
Medical Sciences
(23)
Female
(21)
Pharmacology & Pharmacy
(19)
Pharmacology. Drug Treatments
(17)
Rats
(17)
Anti-Arrhythmia Agents - Pharmacology
(16)
Cardiovascular System
(14)
Dose-Response Relationship, Drug
(14)
Antiarythmic Agents
(13)
Cardiac & Cardiovascular Systems
(13)
Cardiovascular System & Cardiology
(13)
Middle Aged
(12)
Action Potentials - Drug Effects
(10)
Adult
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Canadian boreal forests and climate change mitigation

Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic

A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation

Spontaneous and TMS-related EEG changes as new biomarkers to measure anti-epileptic drug effects

The Mechanism of Atrial Antiarrhythmic Action of RSD1235

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation

Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the Asia–Pacific region: a phase 3 randomized controlled trial

Stabilizing Dog Populations and Improving Animal and Public Health Through a Participatory Approach in Indigenous Communities

Assessment of Potential Pharmacokinetic and Pharmacodynamic Interactions between XEN901 (a Novel NaV1.6 Selective Sodium Channel Blocker) and Phenytoin (a non-selective NaV Blocker) in Adult Healthy Subjects (4682)

Relative bioavailability, pharmacokinetic and food effect assessment of two immediate-release formulations of the NaV1.6-selective sodium channel blocker XEN901: Pediatric Granules and Adult Tablets (4840)

Pharmacokinetic and Food Effect Assessment of XEN496 (Pediatric Formulation of Ezogabine) in Healthy Adults and Relative Bioavailability Assessment with Potiga® (Adult Formulation of Ezogabine) (4918)

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Two Formulations of a Novel Nav1.6 Sodium Channnel Blocker (XEN901) in Healthy Adult Subjects. (4757)

The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults with Focal Epilepsy (X-TOLE) (S19.004)

Children’s understanding of additive concepts

TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-Clonic Seizures (P11-1.012)

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial

Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults with Focal Epilepsy (S19.005)

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial

RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents

Conceptual Knowledge of Arithmetic for Chinese- and Canadian-Educated Adults

Children's multiplication and division shortcuts: Increasing shortcut use depends on how the shortcuts are evaluated

XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44.008)

Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker

Suchergebnisse filtern